Methods and models for assessing efficacy of immunotherapies
AssigneesThe Jackson Laboratory, University of Massachusetts
InventorsLeonard D. Shultz, James Keck, Dale L. Greiner, Michael A. Brehm
Life of this patent
Estimating the term…
Abstract
A method of identifying anti-tumor activity of a test substance is provided along with a genetically-modified, immunodeficient mouse and methods of use, wherein the genetically-modified, immunodeficient mouse enables in vivo investigation of the interactions between the human immune system and human cancer.
Claims11
-12. (canceled)
An immunodeficient transgenic mouse whose genome expresses a transgene encoding human stem cell factor (hSCF), a transgene encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF), a transgene encoding human interleukin-3 (hIL-3), and a transgene encoding human colony-stimulating factor 1 (hCSF1).
An immunodeficient transgenic mouse whose genome:
- (a) expresses a transgene encoding human stem cell factor (hSCF), a transgene encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF), a transgene encoding human interleukin-3 (hIL-3), and a transgene encoding human colony-stimulating factor 1 (hCSF1);
- and
- (b) is homozygous for a Prkdcscid allele and is homozygous for a Il2rgtm1Wjl allele,
- wherein the immunodeficient transgenic mouse has been humanized and engrafted with a human tumor xenograft.
Dependencies are inferred from the claim text.